Vyleesi autoinjector bremelanotide acetate drug profile 2024?

What is Vyleesi, and how does it work?

Vyleesi is an autoinjector that contains the medication bremelanotide acetate, used for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD).

Why is bremelanotide acetate used to treat HSDD?

Research has shown that bremelanotide acetate increases dopamine and nitric oxide release in key regions of the brain, which may help improve sexual desire and arousal in women with HSDD [1].

How does Vyleesi's autoinjector work?

The autoinjector is pre-filled with a single dose of bremelanotide acetate, which is injected subcutaneously into the abdominal area. The injection is typically administered 45 minutes prior to sexual activity, and it has been shown to be effective in improving sexual desire and arousal in women with HSDD [2].

What benefits has Vyleesi shown in clinical trials?

Clinical trials have demonstrated that Vyleesi is effective in improving sexual desire and arousal, as well as overall sexual satisfaction, in premenopausal women with HSDD [3]. The medication has also been shown to be safe and well-tolerated in clinical trials, with common side effects including nausea, headache, and vomiting.

When was Vyleesi approved, and what is its patent status?

Vyleesi was approved by the FDA in November 2019 for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD) [4]. According to DrugPatentWatch.com, the patent for Vyleesi is set to expire in 2034 [5].

References

[1] DrugPatentWatch.com: Bremelanotide Acetate

[2] FDA: Vyleesi (Bremelanotide Acetate) FDA Approval Letter

[3] SpringerLink: Bremelanotide acetate for the treatment of hypoactive sexual desire disorder

[4] FDA: FDA Approves Vyleesi (Bremelanotide Acetate) for Hypoactive Sexual Desire Disorder (FSD)

[5] DrugPatentWatch.com: Vyleesi (Bremelanotide Acetate) Patent Expiration Date